<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01934933</url>
  </required_header>
  <id_info>
    <org_study_id>[2013]2-93</org_study_id>
    <nct_id>NCT01934933</nct_id>
  </id_info>
  <brief_title>Delaying Ossification and Improving Inflammation of Celebrex Plus/or Enbrel Treatment on Active Ankylosing Spondylitis</brief_title>
  <official_title>An Open Clinical Trial to Assess Efficacy for Delaying Ossification and Improving Inflammation of Celebrex Plus/or Enbrel Treatment on Active Ankylosing Spondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label trial to evaluate efficacy for delaying ossification and
      improving inflammation of celebrex treatment on active ankylosing spondylitis (AS). Subjects
      will be randomly divided into three groups (Enbrel group, Celebrex group and Enbrel plus
      Celebrex group) and receive responsable treatment for 54 weeks. Clinical response assessment,
      laboratory assessment and radiology assessment will be recorded. Primary endpoints are the
      magnetic resonance imaging (MRI) Spondyloarthritis Research Consortium of Canada (SPARCC)
      score and the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) of spine and
      sacroiliac(SI) joint, as well as the Assessment of SpondyloArthritis International Society
      (ASAS)20 response rate. Secondary Endpoints include ASAS20, ASAS40, ASAS70 and ASAS5/6
      response rate on each visit and other clinical indexes.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the SPARCC score of spine and SI joint</measure>
    <time_frame>24th weeks</time_frame>
    <description>the MRI SPARCC score of spine and SI joint on 24th week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mSASSS score of spine</measure>
    <time_frame>52th week</time_frame>
    <description>the mSASSS score of spine on 52th week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ASAS20 response rate</measure>
    <time_frame>24th week</time_frame>
    <description>ASAS20 response rate on 24th week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ASAS20 response</measure>
    <time_frame>24th week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS40 response</measure>
    <time_frame>24th week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS70 response</measure>
    <time_frame>24th week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS5/6 response</measure>
    <time_frame>24th week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Inflammation</condition>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>celebrex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>celebrex capsule, 0.2 gram bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enbrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>etanercept injection, 25mg per injection,50mg/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enbrel plus Celebrex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50mg/week Enbrel by hypodermic injection plus Celebrex 0.2 gram bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celebrex</intervention_name>
    <arm_group_label>celebrex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enbrel</intervention_name>
    <arm_group_label>Enbrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enbrel plus Celebrex</intervention_name>
    <arm_group_label>Enbrel plus Celebrex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 65 years

          -  Meet 1984 NewYork modified criteria for AS

          -  BASDAI≥4 or ASDAS score ≥ 2.1

          -  CRP＞6 mg/L or ESR＞28 mm/h

          -  Syndesmophyte quantity ≥2 and ＜16 of spine

          -  Sexually active women of childbearing potential must agree and commit to use a
             medically accepted form of contraception

          -  No active or latent tuberculosis infection.

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  current or previous history of psoriasis or inflammatory bowel disease.

          -  infection with clinical significance within 24 weeks before screening

          -  receipt any bio-agents treatment within 12 weeks before screening

          -  corticosteroids intra-articular injections in last 3 months before the trial

          -  Significant concurrent medical events including: Gastrointestinal ulcer, myocardial
             infarction within 12 months before the screening visit, unstable angina pectoris,
             congestive heart failure.

          -  Alcohol and drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rheumatology Department, the Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2013</study_first_submitted>
  <study_first_submitted_qc>August 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2013</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Gu Jieruo</investigator_full_name>
    <investigator_title>Department of Rheumatology, Third Affiliated Hospital of Sun Yat-sen University</investigator_title>
  </responsible_party>
  <keyword>ossification</keyword>
  <keyword>etanercept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

